Skip to main content
OpenTrials
Completed

NCT Number: NCT03657030

Study of CVN424 in Healthy Subjects

This is a phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose ascending study in healthy subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

PPD Development, LP

Austin, Texas, 78744, United States

About this study

Part 1: Single-Dose Regimen and Fasted-Fed Crossover - For the single-dose regimen, approximately 40 healthy male and female subjects will be enrolled in 1 of 5 single dose cohorts (designated as S1 through S5, respectively) in an ascending fashion.

Part 2: Multiple-Dose Regimen

  • For the multiple-dose regimen, approximately 24 healthy male and female subjects age 18 to 50 years old will be enrolled in 1 of the 3 multiple-dose cohorts (designated as M1 through M3, respectively) in an ascending fashion.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • In the opinion of the Investigator, the subject is capable of understanding and complying with protocol requirements.
  • The subject signs and dates a written informed consent form (ICF) and any required privacy authorization prior to the initiation of any study procedures.
  • Subject is a healthy male or female adult who is 18 to 50 years of age inclusive at the time of ICF and study drug dosing.
  • Subject weighs at least 45 kg (99 lbs) and has a BMI between 18.0 and 30.0 kg/m2, inclusive at Screening.
  • A male subject who is nonsterilized and sexually active with a female partner of childbearing potential* agrees to use adequate contraception* from signing of the ICF throughout the duration of the study and for 12 weeks after last dose.
  • A female subject with no childbearing potential, defined as the subject has been surgically sterilized (hysterectomy, bilateral oophorectomy or tubal ligation) or who are postmenopausal (defined as continuous amenorrhea of at least 2 years and FSH>40 IU/L).

Exclusion criteria

  • Subjects have a known hypersensitivity to any component of the formulation of CVN424.
  • Subjects have evidence of CS neurologic, cardiovascular, pulmonary, hepatic, hematopoietic disease, renal, metabolic, gastrointestinal, urologic, immunologic, endocrine disease, serious allergy, allergic skin rash, psychiatric disorder, or other abnormality that may impact the ability of the subject to participate or potentially confound the study results.
  • There is any finding in the subject's medical history, physical examination, or safety laboratory tests giving reasonable suspicion of a condition that might interfere with the conduct or interpretation of the study.

Treatment and study plan

CVN424

Drug

SAD / MAD

Placebo

Drug

Placebo

Primary outcomes

  1. Evaluation of adverse events

    Time frame: Baseline through 14 days post-dose

    Occurrence of all adverse events from signing of informed consent through end of study treatment.

  2. Evaluation of Hematology

    Time frame: Baseline through 14 days post-dose

    RBC

  3. Evaluation of Vital Signs

    Time frame: Baseline through 14 days post-dose

    Oral Temperature (°C )

  4. Evaluation of Electrocardiograms

    Time frame: Baseline through 14 days post-dose

    Standard 12-lead ECG - QT interval

  5. Evaluation of BMI

    Time frame: Baseline through 14 days post-dose

    Weight and Height will be combined to calculate BMI using the following formula: BMI = weight (kg)/[height (m)]2

  6. Evaluation of Serum Chemistry

    Time frame: Baseline through 14 days post-dose

    ALT

  7. Evaluation of Urinalysis

    Time frame: Baseline through 14 days post-dose

    pH

  8. Evaluation of Vital Signs

    Time frame: Baseline through 14 days post-dose

    Respiration rate

  9. Evaluation of Vital Signs

    Time frame: Baseline through 14 days post-dose

    Pulse rate

  10. Evaluation of Vital Signs

    Time frame: Baseline through 14 days post-dose

    Blood pressure (both systolic and diastolic)

  11. Evaluation of Hematology

    Time frame: Baseline through 14 days post-dose

    WBC with differential (%and absolute) platelets, PT/INR

  12. Evaluation of Hematology

    Time frame: Baseline through 14 days post-dose

    Hemoglobin

  13. Evaluation of Hematology

    Time frame: Baseline through 14 days post-dose

    Hematocrit

  14. Evaluation of Hematology

    Time frame: Baseline through 14 days post-dose

    PT/INR

  15. Evaluation of Hematology

    Time frame: Baseline through 14 days post-dose

    Platelets

  16. Evaluation of Electrocardiograms

    Time frame: Baseline through 14 days post-dose

    Standard 12-lead ECG- QTcB interval

  17. Evaluation of Electrocardiograms

    Time frame: Baseline through 14 days post-dose

    Standard 12-lead ECG - QTcF interval

  18. Evaluation of Electrocardiograms

    Time frame: Baseline through 14 days post-dose

    Standard 12-lead ECG - RR interval

  19. Evaluation of Electrocardiograms

    Time frame: Baseline through 14 days post-dose

    Standard 12-lead ECG - QRS interval

  20. Evaluation of Electrocardiograms

    Time frame: Baseline through 14 days post-dose

    Standard 12-lead ECG - PR interval

  21. Evaluation of Serum Chemistry

    Time frame: Baseline through 14 days post-dose

    Albumin

  22. Evaluation of Serum Chemistry

    Time frame: Baseline through 14 days post-dose

    Alkaline phosphatase

  23. Evaluation of Serum Chemistry

    Time frame: Baseline through 14 days post-dose

    Lipase

  24. Evaluation of Serum Chemistry

    Time frame: Baseline through 14 days post-dose

    AST

  25. Evaluation of Serum Chemistry

    Time frame: Baseline through 14 days post-dose

    Total bilirubin

  26. Evaluation of Serum Chemistry

    Time frame: Baseline through 14 days post-dose

    Direct bilirubin

  27. Evaluation of Serum Chemistry

    Time frame: Baseline through 14 days post-dose

    Total protein

  28. Evaluation of Serum Chemistry

    Time frame: Baseline through 14 days post-dose

    Creatinine

  29. Evaluation of Serum Chemistry

    Time frame: Baseline through 14 days post-dose

    Blood urea nitrogen

  30. Evaluation of Serum Chemistry

    Time frame: Baseline through 14 days post-dose

    Creatine kinase Glucose, Chloride, Bicarbonate

  31. Evaluation of Serum Chemistry

    Time frame: Baseline through 14 days post-dose

    GGT

  32. Evaluation of Serum Chemistry

    Time frame: Baseline through 14 days post-dose

    Potassium

  33. Evaluation of Serum Chemistry

    Time frame: Baseline through 14 days post-dose

    Sodium

  34. Evaluation of Serum Chemistry

    Time frame: Baseline through 14 days post-dose

    Glucose

  35. Evaluation of Serum Chemistry

    Time frame: Baseline through 14 days post-dose

    Chloride

  36. Evaluation of Serum Chemistry

    Time frame: Baseline through 14 days post-dose

    Bicarbonate

  37. Evaluation of Serum Chemistry

    Time frame: Baseline through 14 days post-dose

    Calcium

  38. Evaluation of Urinalysis

    Time frame: Baseline through 14 days post-dose

    Specific gravity

  39. Evaluation of Urinalysis

    Time frame: Baseline through 14 days post-dose

    Protein

  40. Evaluation of Urinalysis

    Time frame: Baseline through 14 days post-dose

    Glucose

  41. Evaluation of Urinalysis

    Time frame: Baseline through 14 days post-dose

    Blood

  42. Evaluation of Urinalysis

    Time frame: Baseline through 14 days post-dose

    Nitrite

  43. Evaluation of Urinalysis

    Time frame: Baseline through 14 days post-dose

    Microscopic Analysis (only if positive dipstick results): RBC/high power field, WBC/high power field, Epithelial cells, casts

Secondary outcomes

  1. Plasma Concentration (AUC) of CVN424

    Time frame: SAD: PK Collection on Day 1-4, and early termination (up to 8 days); MAD: PK Collection on Day 1-10, and early termination (up to 14 days)

    To evaluate the pharmacokinetics of single and multiple doses of CVN424. Pharmacokinetic parameters including, but not limited to area under the plasma concentration-time curve (AUC) from 0 to 24hours (AUC0-24)

  2. Plasma Concentration (Cmax) of CVN424

    Time frame: SAD: PK Collection on Day 1-4, and early termination (up to 8 days); MAD: PK Collection on Day 1-10, and early termination (up to 14 days)

    To evaluate the pharmacokinetics of single and multiple doses of CVN424. Pharmacokinetic parameters including, but not limited to maximum plasma concentration (Cmax).

  3. Food effect by measurement of plasma PK (Cmax)

    Time frame: Baseline through 14 days post-dose

    Assess the effect of food on the bioavailability in the current formulation after digesting a high caloric meal.

  4. Food effect by measurement of plasma PK (AUC)

    Time frame: Baseline through 14 days post-dose

    Assess the effect of food on the bioavailability in the current formulation after digesting a high caloric meal.

Other outcomes

  1. DNA isolation and genotyping

    Time frame: Day 1

    Drug metabolic enzyme and transporter polymorphisms that may contribute to variability in CVN424 will be reported.

    Single-dose -pre-dose

    Multi-dose

    -pre-dose

  2. RNA isolation and genotyping

    Time frame: Day 1 and Day 7

    Single-dose -pre-dose, 8 and 24 hours post dose

    Multi-dose

    -pre-dose, 8 and 24 hours post dose

Sponsors and collaborators

Lead sponsor

Cerevance Beta, Inc.

Industry

Registry information

Official study title

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Doses of CVN424 in Healthy Subjects

Acronym: CVN424

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Sep 4, 2018
Registry last updated
Jul 23, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.